| Name | PPAR gamma |
|---|---|
| Synonyms | HUMPPARG; PAX8/PPARG fusion gene; NR1C3; PPAR gamma; PPAR gamma2; PPARG; PPARG 1; PPARG 2… |
| Name | SMA |
|---|---|
| CAS | sodium 2-chloroacetate |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 20212046 | Zhang L, Xie P, Wang J, Yang Q, Fang C, Zhou S, Li J: Impaired peroxisome proliferator-activated receptor-{gamma} contributes to phenotypic modulation of vascular smooth muscle cells during hypertension. J Biol Chem. 2010 Mar 8. |
11(0,0,0,11) | Details |
| 20037602 | Zou R, Xu G, Liu XC, Han M, Jiang JJ, Huang Q, He Y, Yao Y: PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis. . Acta Pharmacol Sin. 2010 Jan;31(1):43-50. Epub 2009 Dec 28. |
7(0,0,0,7) | Details |
| 19271115 | Masamune A, Shimosegawa T: Signal transduction in pancreatic stellate cells. 1373.e1-2. Epub 2010 Feb 13. Signaling molecules, such as peroxisome proliferator-activated receptor-gamma (PPAR-gamma), Rho/Rho kinase, nuclear factor-kappaB (NF-kappaB), mitogen-activated protein (MAP) kinases, phosphatidylinositol 3 kinase (PI3K), Sma- and Mad-related proteins, and reactive species (ROS) might be candidates for the development of anti-fibrosis therapy targeting PSCs. |
6(0,0,1,1) | Details |
| 19286977 | Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, Phipps RP, Sime PJ: Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Anat Rec. 2009 Jul;292(7):1045-61. |
6(0,0,0,6) | Details |
| 20015942 | Lee YJ, Han HJ: Troglitazone ameliorates high glucose-induced EMT and dysfunction of SGLTs through PI3K/Akt, GSK-3{beta}, Snail1, and {beta}-catenin in renal proximal tubule cells. Am J Physiol Renal Physiol. 2009 Dec 16. Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists ameliorate renal fibrotic lesions in diabetic nephropathy. |
5(0,0,0,5) | Details |
| 19484746 | Takeda K, Okamoto M, de Langhe S, Dill E, Armstrong M, Reisdorf N, Irwin D, Koster M, Wilder J, Stenmark KR, West J, Klemm D, Gelfand EW, Nozik-Grayck E, Majka SM: Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. Scand J Gastroenterol. 2009;44(3):358-65. We hypothesized that the maintenance of peroxisome proliferator-activated receptor gamma (PPARgamma) signaling is important for normal lung morphogenesis and treatment with PPARgamma agonists could protect against CLD and airway hyperreactivity (AHR) following chronic hyperoxic exposure. |
4(0,0,0,4) | Details |
| 18274641 | Wang W, Liu F, Chen N: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists attenuate the profibrotic response induced by TGF-beta1 in renal interstitial fibroblasts. Mediators Inflamm. 2007;2007:62641. |
4(0,0,0,4) | Details |
| 19002105 | Kawai T, Masaki T, Doi S, Arakawa T, Yokoyama Y, Doi T, Kohno N, Yorioka N: PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Am J Respir Cell Mol Biol. 2009 Dec;41(6):722-30. Epub 2009 Mar 13. |
3(0,0,0,3) | Details |
| 18991162 | Nan YM, Fu N, Wu WJ, Liang BL, Wang RQ, Zhao SX, Zhao JM, Yu J: prevents nutritional fibrosis and steatohepatitis in mice. J Gastroenterol. 2009;44(4):249-60. Epub 2009 Mar 7. RESULTS: At week 8, MCD-diet-induced fibrosing NASH models showed increased serum ALT and AST levels, severe hepatic steatosis, and infiltration of inflammation and fibrosis which, associated with down-regulated PPAR gamma mRNA and protein expression, up-regulated alpha-SMA protein expression and enhanced TGF-beta1, CTGF mRNA and protein expression. |
3(0,0,0,3) | Details |
| 19143945 | Efrati S, Berman S, Chachashvili A, Cohen N, Siman-Tov Y, Averbukh Z, Weissgarten J: treatment attenuates renal tissue inflammation generated by urinary tract obstruction. Nephrology. 2009 Apr;14(2):189-97. AIM: Peroxisome proliferator-activated receptor (PPAR)-gamma activation by decreases manifestation of intrarenal inflammatory hallmarks. |
3(0,0,0,3) | Details |
| 18473419 | Chen H, He YW, Liu WQ, Zhang JH: prevents murine hepatic fibrosis induced by Schistosoma japonicum. World J Gastroenterol. 2008 May 14;14(18):2905-11. NF-kappaB binding activity and expression of PPAR gamma-mRNA were determined by Western blot assay and real-time quantitative PCR. |
3(0,0,0,3) | Details |
| 20205597 | Lin Q, Fang LP, Zhou WW, Liu XM: inhibits migration, proliferation, and phenotypic differentiation in cultured human lung fibroblasts. Exp Lung Res. 2010 Mar;36(2):120-8. Recent studies have indicated that peroxisome proliferator-activated receptor gamma (PPARgamma) is capable of modulating inflammation, which prompted us to investigate the potential of PPARgamma ligands as lung protective agents in pulmonary fibrosis. |
3(0,0,0,3) | Details |
| 18035585 | Yu JH, Kim KH, Kim H: SOCS 3 and PPAR-gamma ligands inhibit the expression of IL-6 and TGF-beta1 by regulating JAK2/STAT3 signaling in pancreas. Int J Biochem Cell Biol. 2008;40(4):677-88. Epub 2007 Oct 12. |
2(0,0,0,2) | Details |
| 19304912 | Dasgupta C, Sakurai R, Wang Y, Guo P, Ambalavanan N, Torday JS, Rehan VK: Hyperoxia-induced neonatal rat lung injury involves activation of TGF-{beta} and Wnt signaling and is protected by Lab Invest. 2009 Jan;89(1):47-58. Epub 2008 Nov 10. These changes were also accompanied by upregulation of myogenic marker proteins alpha-smooth muscle actin (alpha-SMA) and calponin but significant downregulation of the lipogenic marker peroxisome proliferator-activated receptor-gamma (PPARgamma) expression. |
2(0,0,0,2) | Details |
| 19894400 | Lee HM, Kang HJ, Park HH, Hong SC, Kim JK, Cho JH: Effect of peroxisome proliferator-activated receptor gamma agonists on myofibroblast differentiation and collagen production in nasal polyp-derived fibroblasts. Ann Otol Rhinol Laryngol. 2009 Oct;118(10):721-7. |
2(0,0,0,2) | Details |
| 19816704 | Karaoz E, Dogan BN, Aksoy A, Gacar G, Akyuz S, Ayhan S, Genc ZS, Yuruker S, Duruksu G, Demircan PC, Sariboyaci AE: Isolation and in vitro characterisation of dental pulp stem cells from natal teeth. Histochem Cell Biol. 2010 Jan;133(1):95-112. Epub 2009 Oct 9. Ultrastructural characteristics of hNDP-SCs showed more developed and metabolically active cells. hNDP-SCs and hBM-MSCs expressed some adipogenic (leptin, adipophilin and PPARgamma), myogenic (desmin, myogenin, myosinIIa, and alpha-SMA), neurogenic (gamma-enolase, MAP2a,b, c-fos, nestin, NF-H, NF-L, GFAP and betaIII tubulin), osteogenic (osteonectin, osteocalcin, osteopontin, Runx-2, and type I collagen) and chondrogenic (type II collagen, SOX9) markers without any stimulation towards differentiation under basal conditions. |
1(0,0,0,1) | Details |
| 17903364 | Wang XM, Chen DF: [Effects of on Kruppul-like factor 6 (KLF6) signaling in the livers of rats with nonalcoholic fatty liver fibrosis]. Zhonghua Gan Zang Bing Za Zhi. 2007 Sep;15(9):649-53. CONCLUSION: to a certain extent, can inhibit KLF6-TGFalpha1 signal transduction by inducing expression of PPAR-gamma, and then inhibit the activation of hepatic stellate cells and minimize hepatic fibrosis. |
1(0,0,0,1) | Details |
| 20004661 | McHutchison J, Goodman Z, Patel K, Makhlouf H, Rodriguez-Torres M, Shiffman M, Rockey D, Husa P, Chuang WL, Levine R, Jonas M, Theodore D, Brigandi R, Webster A, Schultz M, Watson H, Stancil B, Gardner S: Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010 Apr;138(4):1365-73 BACKGROUND & AIMS: Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activates peroxisome proliferator-activated receptor gamma (PPARgamma) and inhibits stellate cell activation. |
1(0,0,0,1) | Details |